Transthyretin Cardiac Amyloidosis
13
5
7
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (13)
EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac Amyloidosis
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis
[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
Bronx Transthyretin Amyloid Cardiomyopathy Database
Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery
Exercise Training in Transthyretin Cardiac Amyloidosis
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)